CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
Open Access
- 5 June 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (11) , 2764
Abstract
The advent of CD19-specific chimeric antigen receptor (CAR) T cells has proven to be a powerful asset in the arsenal of cancer immunotherapy of acute lymphoblastic leukemia and certain B cell lymphomas. However, a sizable portion of patients treated with CD19-CAR T cells relapse with CD19-negative cancer cells, necessitating the quest for back-up antigens. Chondroitin sulfate proteoglycan 4 (CSPG4) expression has been reported on leukemic blasts bearing the ill-fated MLL 11q23 rearrangement. We aimed at exploring the use of CSPG4-specific CAR T cells against mixed-lineage leukemia (MLL)-rearranged leukemic blasts, using the precursor B cell leukemia cell line KOPN8 (MLL–MLLT1 translocation) as a model. First, we confirmed CSPG4 expression on KOPN8 cells. Bulk T cells electroporated with mRNA encoding a CSPG4-specific CAR upregulated activation markers and secreted the Th1 cytokines TNF and IFNγ in an antigen-specific manner upon co-culture with KOPN8 cells. More importantly, CSPG4-specific CAR T cells evinced specific degranulation towards KOPN8 cells and specifically lysed KOPN8 target cells in chromium lysis experiments. CSPG4 is a well-established CAR target in cutaneous melanoma. Here, we provide proof-of-principle data for the use of CSPG4-specific CAR T cells against MLL-translocated leukemias.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SCHA 1247/3-1)
This publication has 61 references indexed in Scilit:
- Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4Cancer Research, 2011
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck ActivationMolecular Therapy, 2011
- Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2011
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivoMolecular Cancer, 2010
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodiesCancer Immunology, Immunotherapy, 2008
- A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cellsMelanoma Research, 2008
- Targeting Pericytes Diminishes Neovascularization in Orthotopic Uveal Melanoma in Nerve/Glial Antigen 2 Proteoglycan Knockout MouseOphthalmic Research, 2006
- Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterationsLeukemia, 2003
- Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10−/CD24−/CD65s+/CD15+ B-cell phenotypeLeukemia, 2003